---
document_datetime: 2026-01-30 08:46:29
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trulicity-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: trulicity-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.8641347
conversion_datetime: 2026-02-01 20:42:36.13362
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Trulicity

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                       |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------|
| Variation type IB /  | This was an application for a group of | 30/01/2026                          |                                             | SmPC,                            | To update Sections 2 and 4.4 of the SmPC, and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000321382                     | variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted A. ADMINISTRATIVE CHANGES - A.1 Change in the name and/or address of the marketing authorisation holder - Accepted   |            | Labelling and PL   | Section 2 of the PL with information on the excipient polysorbate, based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. In addition, the MAH took the opportunity to remove the QR code from the carton and PL. Furthermore, the MAH implemented editorial changes to the Product Information in IT and PL to align the pharmaceutical form wording with the   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000309292 | This was an application for a group of variations.                                                                                                                                                              | 15/01/2026 |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000310299 | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the                                                                                                                                                                 | 25/11/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                     | finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|
| Variation type II / | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted | 04/09/2025 | EMA/VR/0000279574 |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000267403   | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted   | 04/07/2025   | N/A   |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type IB / EMA/VR/0000267964   | This was an application for a group of variations. B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.f The scale for a biological/immunological medicinal product is increased / decreased without process change (e.g. duplication of line) - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the                                                                                                        | 23/06/2025   | N/A   |

<div style=\"page-break-after: always\"></div>

|                                       | finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000275826 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer | 23/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                                                                                                                                                                                           |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000245948 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Other changes - Accepted | 24/02/2025 | N/A |
| Variation type II / EMA/VR/0000244601 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a                                                   | 20/02/2025 |     |

<div style=\"page-break-after: always\"></div>

|                                       | biological/immunological method - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted                                                                                                                                    |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000246167 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 23/01/2025 | N/A |